Misoprostol opposes hypoxia-induced cell death 2 Abstract The cellular response to hypoxia involves the activation of a conserved pathway for gene expression regulated by the transcription factor complex called hypoxia-inducible factor (HIF). This pathway has been implicated in both the adaptive response to hypoxia and in several hypoxic-ischemic related pathologies. Perinatal hypoxic injury, often associated with prematurity, leads to multi-organ dysfunction resulting in significant morbidity and mortality. Using a rodent model of neonatal hypoxia and several representative cell lines, we observed HIF1α activation and down-stream induction of the cell death gene Bnip3 in brain, large intestine, and heart which was mitigated by administration of the prostaglandin E1 analog misoprostol. Mechanistically, we determined that misoprostol inhibits full-length Bnip3 (Bnip3-FL) expression through PKAmediated NF-κB (P65) nuclear retention, and the induction of pro-survival splice variants. We observed that the dominant small pro-survival variant of Bnip3 in mouse cells lacks the third exon (Bnip3ΔExon3), whereas human cells produce a pro-survival BNIP3 variant lacking exon 2 (BNIP3ΔExon2). In addition, these small Bnip3 splice variants prevent mitochondrial dysfunction, permeability transition, and necrosis triggered by Bnip3-FL by blocking calcium transfer from the sarco/endoplasmic reticulum to the mitochondria. Furthermore, misoprostol and Bnip3ΔExon3 promote nuclear calcium accumulation, resulting in HDAC5 nuclear export, NFAT activation, and adaptive changes in cell morphology and gene expression. Collectively, our data suggests that misoprostol can mitigate the potential damaging effects of hypoxia on multiple cell types by activating adaptive cell survival pathways through Bnip3 repression and alternative splicing.
Introduction
Bnip3ΔExon3, resulting a conserved C-terminal amino acid sequence. Mechanistically, we determined that a combination of NF-κB and HIF1α activation alters BNIP3 splicing and induces the expression of the smaller variants. Finally, we experimentally altered the ratio of Bnip3-FL to Bnip3ΔExon3, and Bnip3-FL to BNIP3ΔExon2 in multiple cell types, and observed that the smaller variants prevent mitochondrial permeability transition and cell death by inhibiting mitochondrial calcium accumulation and promoting nuclear calcium-dependent cell adaptation. These findings suggest that prostaglandin signaling may play an important developmental role that can be used therapeutically to circumvent many of the morbidities associated with neonatal hypoxia.
Results

Misoprostol inhibits Bnip3-FL expression in vivo:
Previously, we demonstrated that misoprostol could inhibit cell death in cultured enterocytes exposed to nutrient stress 22 . Moreover, our previous work implicated the hypoxia-inducible gene Bnip3 in this process. In order to further these studies in vivo, we exposed neonatal rats to 7 days of hypoxia (10% oxygen), prior to weaning, with and without misoprostol treatment (10 µg/kg; subcutaneous). This protocol has been previously shown to induce cognitive impairment consistent with HIE 23, 24 . Bnip3 expression analysis by western blot demonstrated increased Bnip3-FL expression in the hippocampus, large intestine, and heart of hypoxia-exposed animals, which was completely abrogated by concurrent misoprostol treatment ( Figure 1A) .
Canonical NF-κB signaling has been previously shown to be a critical regulator of Bnip3 expression during cardiac hypoxia (reviewed by Gordon et al 15 ). Moreover, protein kinase-A (PKA) has been shown to phosphorylate P65 of the NF-κB complex at Serine-276 to promote nuclear accumulation 18 . Thus, we tested the hypothesis that misoprostol could repress Bnip3-FL expression through a conserved PKA-and NF-κB-dependent mechanism. Using a geneticallyencoded plasmid-based PKA biosensor (pPHT-PKA) 25 , we observed marked PKA activation in HCT-116 cells treated with misoprostol ( Figure 1B , C). Consistent with our hypothesis, we observed increased nuclear localization of a human P65-GFP construct in misoprostol treated HCT-116 cells ( Figure 1D , E). However, when cells were co-treated with misoprostol and the PKA-inhibitor H89, this effect was lost and P65 was retained in the cytoplasm. To further investigate the role of NF-κB signalling in this misoprostol-induced response, we expressed the same P65-GFP construct concurrently with a dominant negative form of the Inhibitor of kappa-B (IκB S32A, S36A or IκB-SA), in misoprostol treated HCT-116 cells. Here we observed that the misoprostol-induced nuclear localization was lost in the presence of IκB-SA ( Figure 1F , G). Additionally, we performed nuclear and cytosolic fractionation studies to biochemically confirm the observed phenomenon of P65-nuclear localization. In HCT-116 cells treated with a vehicle control or misoprostol, we observed that misoprostol treatment had no effect on total P65 expression ( Figure 1H ). However, consistent with our P65-GFP findings, we observed an increase in levels of nuclear P65. Next, we assessed the role of misoprostol in the regulation of P65 phosphorylation at a known PKA phosphorylation site, serine-276. Shown in Figure 1I , we observed that misoprostol treatment increased phospho-p65. The migration of this band is consistent with information provided by the manufacturer.
To confirm that NF-κB regulates BNIP3-FL expression in HCT-116 cells, we expressed P65 in this cell line and analyzed BNIP3-FL expression by western blot. Ectopic expression of P65 reduced BNIP3-FL protein levels ( Figure 1J ). Furthermore, we expressed wild-type P65, and a P65 mutant form, where the PKA phospho-acceptor site, Ser-276, was mutated to a neutral alanine (P65-S276A) thereby ablating phosphorylation at this site. This experiment confirmed that wild-type P65 represses BNIP3FL expression; however, when Ser-276 is neutralized BNIP3-FL expression is enhanced ( Figure 1K ).
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Collectively, these findings support a model of Bnip3-FL repression where misoprostol activates PKA signaling to promote P65 phosphorylation at the Ser-276 site, leading to nuclear accumulation of the NF-κB complex and subsequent repression of BNIP3-FL expression.
Discovery of BNIP3ΔExon2:
Recently, it was reported that the rat Bnip3 pre-mRNA undergoes alternative splicing to yield a full-length protein containing all six exons, and a small splice variant lacking the third exon (Bnip3ΔExon3) 21 . Moreover, the fusion of exon 2 to exon 4 in the Bnip3ΔExon3 mRNA results in a frame-shift and the generation of a pre-mature stop codon. Functionally, Bnip3ΔExon3 acts as an endogenous inhibitor of BNIP3-FL, blocking hypoxia-and nutrient stress-induced cell death 21, 22 . Based on our findings that misoprostol supressed BNIP3-FL expression elicited by neonatal hypoxia, we used semi-quantitative RT-PCR to evaluate whether misoprostol could alter Bnip3 splicing. Using primers that spanned the exon 2-4 junction, we detected a smaller amplicon representing Bnip3ΔExon3 in RNA isolated from hearts of neonatal rats treated with misoprostol, but not in vehicle treated animals (Figure 2A ).
To our knowledge, Bnip3ΔExon3 expression has not been reported at the protein level. Recently, a commercially available antibody targeting exon 1 of BNIP3 has come to market. This antibody could hypothetically detect smaller BNIP3 variants; however, this antibody only detects human BNIP3 protein (Cell Signaling Technology; #44060). In order to evaluate the role of misoprostol promoting BNIP3 splicing in human cell lines, we attempted to clone human BNIP3ΔExon3. We designed a forward primer encompassing the 5'-ATG of human BNIP3 and a reverse primer containing the premature stop codon identified in mouse Bnip3ΔExon3. Restriction enzyme sites were incorporated into these primers to allow easy ligation into pcDNA3 and sequencing. Interestingly, in three distinct human cells lines we observed three amplicons generated by these primers ( Figure 2B ). Based on sequencing analysis, the largest amplicon represents a fragment of BNIP3-FL. However, the middle and smallest amplicons represent splice variants lacking exon 2 (BNIP3ΔExon2) and exons 2 and 3 (BNIP3ΔExon2+3), respectively. Using the same approach in three representative mouse cell lines, we identified a fragment of BNIP3-FL, Bnip3ΔExon3, and Bnip3ΔExon2+3 ( Figure 2B ). These findings suggest that Bnip3 is differentially spliced in human versus rodent cells ( Figure 2C ). The variants with two missing exons form very small peptides due to early stop codons in their reading frame ( Figure 2C and Supplemental). However, the mouse Bnip3ΔExon3 and human BNIP3ΔExon2 share the same frame shift, and generate a conserved C-terminus when translated ( Figure 2D ) (Alignment performed on the CLUSTAL O 1.2.4 multiple sequence alignment tool). Importantly, when expressed in HCT-116 cells, we were able to detect both human HA-BNIP3-FL and HA-BNIP3ΔExon2 with the commercially available N-terminal BNIP3 antibody ( Figure 2E ), suggesting that detection of endogenous protein of these small BNIP3 splice variants is possible in human cells and tissue. However, this commercially-available antibody could not detect mouse Bnip3ΔExon3 protein. To solve this, we designed a custom Bnip3 antibody specifically targeted to a region of the N-terminus of full-length Bnip3 that is conserved in humans and rodents. We then performed a series of validation experiments to test this custom antibody. First, we tested if the antibody was able to detect HA-or myc-tagged versions of BNIP3-FL and Bnip3∆Exon3 in a side-by-side comparison with commercial HA-tag or myc-tag antibodies. As shown in Figure 2F , the antibody successfully detects both human and mouse full length BNIP3, and what is likely the monomeric and dimeric forms of BNIP3-FL at the approximate sizes of 25 and 63 kDa, respectively. Importantly, we could detect the smaller mouse isoform, Bnip3ΔExon3, but not the human isoform, BNIP3ΔExon2, as this epitope spans the second exon in the human gene. Second, we used an siRNA targeted to the unique sequence of Bnip3∆Exon3 to knockdown endogenous Bnip3ΔExon3 protein ( Figure 2G ). This set of experiments provides evidence that both the custom antibody successfully detects Bnip3ΔExon3, and that the siRNA knockdown of Bnip3ΔExon3 shows specificity for Bnip3ΔExon3 and has little effect on the expression of fulllength Bnip3 protein. To our knowledge this is the first documentation of Bnip3ΔExon3 detected as a protein; furthermore, we demonstrated endogenous expression of this protein in a rodent cardiac cell line.
In silico domain mapping of the smaller BNIP3 variants revealed that neither mouse Bnip3ΔExon3 nor human BNIP3ΔExon2 contain the atypical BH3 domain of the full-length splice variants, and only mouse Bnip3ΔExon3 retained the N-terminal LC3 interacting region (LIR) ( Figure 2H ). Interestingly, both mouse Bnip3ΔExon3 and human BNIP3ΔExon2 contain Cterminal WH2 actin binding motifs and a di-lysine ER retention signal (ER). Moreover, the Cterminal region of human BNIP3ΔExon2 contains a predicted bipartite nuclear localizing signal (NLS). Finally, the Phyre2 (Protein Homology/analogY Recognition Engine V 2.0) web portal for protein modeling provided the predicted structure of the smaller Bnip3 splice variants, described previously 26, 27 . We used the predicted structure of mouse Bnip3-FL for comparison ( Figure 2I ). Intriguingly, the Phyre2 portal predicted a remarkably similar structure for both mouse Bnip3ΔExon3 and human BNIP3ΔExon2 ( Figure 2J , K), which supports the idea that they may function in a similar biological manner.
HIF1α and NF-κB P65 regulate BNIP3 expression and splicing:
To further investigate how the expression of the smaller BNIP3 variants are regulated, we treated HCT-116 with misoprostol, and the HIFα stabilizer cobalt chloride (CoCl 2 ) for 16-hours. Using semi-quantitative RT-PCR and primers designed to detect both BNIP3-FL and BNIP3ΔExon2, we observed that misoprostol alone reduced BNIP3-FL expression, while CoCl 2 treatment induced the expression of both BNIP3 splice variants ( Figure 3A ). However, in the presence of misoprostol, we observed proportionally more BNIP3ΔExon2. Next, we preformed the same experiment using the N-terminal BNIP3 antibody, combined with western blot analysis, and observed induction of BNIP3-FL concurrent with increased HIF1α when treated with CoCl 2 ( Figure 3B ). When combined with misoprostol, CoCl 2 induced the expression of a 11-17 kDa band as detected by the N-terminal BNIP3 antibody, consistent with migration pattern of BNIP3ΔExon2 observed in Figure 2E . Interestingly, at this dose and time point misoprostol did not affect BNIP3-FL protein expression. To reconcile this observation with our misoprostol findings in vivo, we extended our time-course and treated HCT-116 cells with CoCl 2 and misoprostol for 36-hours. At this time point misoprostol attenuated CoCl 2 induced BNIP3-FL expression, while the expression BNIP3ΔExon2 was less effected ( Figure 3C ). These findings suggest that misoprostol alters BNIP3 splicing at earlier time points then represses BNIP3-FL expression at later time points. Next, we performed a gain-of-function experiment in HCT-116 cells to assess the expression of BNIP3 splice variants by western blot. Shown in Figure 3D , expression of HIF1α induced the expression of BNIP3-FL; however, when HIF1α expression was combined with NF-κB P65, BNIP3ΔExon2 expression was increased and BNIP3-FL expression was proportionally decreased.
To evaluate the functional consequences of altered BNIP3 splicing, we transfected HCT-116 cells with HIF1α and NF-κB P65, and assessed cell viability by using calcein-AM, which stains viable cells green, and ethidium homodimer-1, which stains necrotic cells red. HIF1α expression increased the percentage of ethidium positive (necrotic) cells, whereas the combination of both HIF1α and NF-κB P65 had no effect on cell death ( Figure 3E ). Next, we treated HCT-116 cells with CoCl 2 , to induce a HIF/BNIP3 response, with or without the addition of misoprostol. Overnight treatment of cells with CoCl 2 significantly increased the percentage of ethidium positive cells ( Figure 3F , G). However, when cells were treated with both CoCl 2 and misoprostol, the percentage of ethidium positive cells was significantly reduced. To evaluate the role of BNIP3-FL in CoCl 2 -induced cell death, we performed Bnip3-FL knockdown studies. Prior to functional assays, we transfected HCT-116 cells with si-BNIP3-FL, and treated with CoCl 2 . We observed that the siRNA reduced BNIP3-FL expression without affecting BNIP3ΔExon2 expression ( Figure  3H ). We then assessed the functional consequences of this knockdown, by demonstrating that that si-BNIP3-FL is sufficient to prevent CoCl 2 -induced necrotic cell death in HCT-116 cells ( Figure 3I ). Furthermore, in parallel gain-of-function experiments, we transfected HCT-116 cells with Bnip3-FL to induced necrosis, and added either Bnip3ΔExon3 or BNIP3ΔExon2. Shown in Figure 3J and 3K, Bnip3-FL increased the percentage of ethidium positive cells, which was reduced by co-expression of either Bnip3ΔExon3 or BNIP3ΔExon2. These findings suggest that both Bnip3ΔExon3 and BNIP3ΔExon2 act as endogenous inhibitors of Bnip3-FL-induced cell death.
Misoprostol and Bnip3ΔExon3 protect against hypoxia-induced mitochondrial dysfunction:
Clinical evidence suggests that cardiac dysfunction, and the presence of serum cardiac marker-proteins, are important predictors of morbidity and mortality during neonatal hypoxia/asphyxia 5, 6 . Moreover, recent experimental evidence has implicated mitochondrial permeability transition, rapid dissipation of the mitochondrial membrane potential, and mitochondrial superoxide production as pre-cursor events leading to regulated necrosis 28, 29 . Thus, we evaluated the effect of misoprostol and Bnip3ΔExon3 on hypoxia-induced mitochondrial dysfunction in primary neonatal ventricular myocytes. First, we assessed mitochondrial membrane potential by TMRM staining. Shown in Figure 4A and B, exposure to hypoxia (10% O 2 for 48-hours) reduced mitochondrial membrane potential, which was completely attenuated by treatment with misoprostol. Next, we evaluated mitochondrial super oxide levels with the dye MitoSOX, and observed that hypoxia-induced super oxide accumulation was prevented by misoprostol treatment (Figure 4C , D). We also evaluated mitochondrial respiration in primary ventricular myocytes using a metabolic flux analyzer (Seahorse, XF24). Consistent with our TMRM observations, 48-hours of hypoxia exposure reduced both basal and maximal respiration, which was completely abrogated by misoprostol treatment (Figure 4E , F). Finally, we generated a Bnip3ΔExon3 lentivirus and evaluated if this Bnip3 splice variant could overcome mitochondrial perturbations induced by hypoxia exposure. We found that primary myocytes transduced with Bnip3ΔExon3 lentivirus gained resistance to mitochondrial depolarization caused by hypoxia ( Figure 4G , H). Collectively, these findings demonstrate that both misoprostol and Bnip3ΔExon3 confer some degree of protection against hypoxia-induced mitochondrial dysfunction in primary neonatal cardiomyocytes.
Bnip3-FL-induced mitochondrial perturbations are inhibited by the small Bnip3 splice variants:
Next, we evaluated how misoprostol and Bnip3-FL affect mitochondrial membrane potential in human (HCT-116) and rodent (H9c2) cell lines. Staining with TMRM, we observed that CoCl 2 significantly reduced mitochondrial membrane potential; however, co-treatment with misoprostol completely abolished this effect ( Figure 5A , B). We assessed mitochondrial membrane potential in cultured H9c2 cells, where CMV-GFP was used to identify transfected cells. Shown in Figure 5C , knockdown of Bnip3∆Exon3 reduced the effectiveness of misoprostol in moderating the depolarization caused by treatment with CoCl 2 . Therefore, we decided to directly examine the effects of the smaller splice variants on membrane potential in transfection experiments. Bnip3-FL expression reduced TMRM staining, where co-expression of Bnip3ΔExon3 and Bnip3-FL restored TMRM staining to levels comparable to control ( Figure 5D ), and BNIP3ΔExon2 had the same effect ( Figure 5E , F). Next, we assessed mitochondrial permeability transition by staining H9c2 cells with calcein-AM, where cobalt chloride is used to quench the cytosolic emission 30 . With this technique, loss of mitochondrial puncta is interpreted as permeability transition. A CMV-dsRed plasmid was included to identify transfected cells. Expression of Bnip3-FL in H9c2 cells resulted in a significant decrease in the number of transfected cells with observable puncta; whereas, co-expression of either Bnip3ΔExon3 (Figure Misoprostol opposes hypoxia-induced cell death 8 5G, H) or BNIP3ΔExon2 ( Figure 5I ) restored the number of punctate cells. Finally, to evaluate whether these mitochondrial perturbations translated into an effect on cell viability, we transfected H9c2 cells with Bnip3-FL and with and without Bnip3ΔExon3, then assessed the percentage of ethidium homodimer positive cells. As shown in Figure 5J and K, Bnip3-FL-induced cell death was reversed in the presence of Bnip3ΔExon3 in this cardiac cell line.
Bnip3 splice variants regulate mitochondrial calcium homeostasis:
An important component of regulated necrosis involves permeability transition triggered by elevations in mitochondrial calcium 29, 31, 32 , where calcium release from the endoplasmic reticulum can serve as a trigger for permeability transition 33, 34 . To more fully investigate the role of cellular calcium in Bnip3-regulated permeability transition, we used organelle-targeted plasmidbased calcium biosensors, called GECOs (Genetically Encoded Ca 2+ indicators for Optical imaging) 35 . We used the mitochondrial matrix-targeted red GECO, known as mito-carmine (mito-Car-GECO) and ER-targeted LAR-GECO (ER-LAR-GECO) 36 to test the hypothesis that the effects of Bnip3 splice variants on mitochondrial function and cell viability are interconnected with calcium signaling. Shown in Figure 6A and B, expression of Bnip3-FL reduced steady-state ER calcium levels. Surprisingly, Bnip3ΔExon3 also reduced ER calcium content and no cumulative effect on calcium release was observed with co-expression of both splice variants. Next, we examined if mitochondria were the destination of the released calcium using the mitochondrialtargeted GECO ( Figure 6C , D). We observed that Bnip3-FL increased mitochondrial calcium levels. Whereas Bnip3ΔExon3 had no effect when acting alone, but when together with Bnip3-FL, Bnip3ΔExon3 attenuated mitochondrial calcium accumulation. A similar phenomenon was observed with BNIP3ΔExon2 ( Figure 6E ). Likewise, misoprostol had a similar effect on mitochondrial calcium accumulation when co-treating with CoCl 2 , to induce Bnip3-FL expression ( Figure 6F ). Moreover, knock-down of Bnip3-FL with an siRNA prevented CoCl 2 -induced mitochondrial calcium accumulation ( Figure 6G ). In concert with our earlier observations, knockdown of Bnip3ΔExon3 reduced the effectiveness of misoprostol in moderating the mitochondrial calcium load ( Figure 6H ). These observations led us to hypothesize that Bnip3ΔExon3 attenuates mitochondrial permeability transition by blocking mitochondrial calcium uptake, but not the release of calcium from the ER. To test this hypothesis, we expressed Bnip3-FL, with and without the inositol triphosphate receptor (IP3R) inhibitor 2-APB, and evaluated mitochondrial calcium levels. Shown in Figure 6I , Bnip3-FL-induced mitochondrial calcium accumulation was attenuated by 2-APB, suggesting that the ER calcium release is buffered by the mitochondria. Next, we evaluated whether pharmacological inhibition of the mitochondrial calcium uniporter (MCU) with Ru360, or inhibition of the mitochondrial voltage-dependent anion channel (VDAC) with DIDS, could affect Bnip3-FL-induced mitochondrial calcium accumulation. We observed that both Ru360 and DIDS prevented mitochondrial calcium accumulation caused by Bnip3-FL ( Figure 6J ). Interestingly, a combination of both inhibitors did not produce any additional effect, and that levels of mitochondrial calcium when treated with the inhibitors was similar in magnitude to those observed with co-expression of Bnip3ΔExon3. Finally, we used the SERCA inhibitor thapsigargin (Thaps) to circumvent a regulated ER calcium release. Shown in Figure 6K , thapsigargin treatment led to mitochondrial calcium accumulation that was attenuated by expression of Bnip3ΔExon3, indicating that Bnip3ΔExon3 affects entry of calcium into the mitochondria. Collectively, these observations support our hypothesis that Bnip3-FL promotes ER calcium release that accumulates in the mitochondrial matrix, while Bnip3ΔExon3 and BNIP3ΔExon2 serve to block mitochondrial calcium accumulation.
Bnip3 was originally discovered as an interacting partner of the pro-survival protein BCL-2 37 . Interestingly, BCL-2 has been implicated as an important regulator of cellular calcium signaling through multiple mechanisms, including blocking mitochondrial calcium uptake through inhibition of VDAC channels 34, 38 . Thus, we investigated the possibility of BCL-2 involvement in Bnip3ΔExon3-regulated calcium signaling. Specifically, we tested if Bnip3ΔExon3 could alter the cellular location of BCL-2. We expressed Flag-tagged BCL-2, with and without HA-tagged Bnip3ΔExon3, in HCT-116 cells and performed mitochondrial and cytosolic fractionation. Western blot analysis of these fractions revealed that Bnip3ΔExon3 reduced the cytosolic levels of BCL-2 and increased the mitochondrial BCL-2 levels, without impacting the whole-cell expression of BCL-2 ( Figure 7A ). These findings suggest that Bnip3ΔExon3 promotes mitochondrial translocation of BCL-2. Additionally, we observed that both BCL-2 and the structurally related protein MCL-1, were capable of blocking Bnip3-FL-induced mitochondrial calcium accumulation ( Figure 7B ).
Our observation that Bnip3ΔExon3 did not block ER calcium release, but did prevent mitochondrial calcium accumulation, led us to investigate the nucleus as a possible subcellular destination for this calcium. Using a GECO-based calcium biosensor fused to a nuclear localization signal (NLS-R-GECO) 35 , we evaluated the effect of Bnip3ΔExon3 on nuclear calcium content. Shown in Figure 7C and D, Bnip3ΔExon3 increased nuclear calcium levels, whereas Bnip3-FL had no effect. Although not as marked of an elevation as observed with Bnip3ΔExon3 alone, nuclear calcium remained elevated when Bnip3-FL was co-expressed with Bnip3ΔExon3. Similar effects on nuclear calcium were observed with BNIP3ΔExon2 ( Figure 7E , F). In addition, we observed that Bnip3ΔExon3-induced calcium accumulation was prevented by the IP3R inhibitor 2-APB ( Figure 7G , H), providing evidence for a dependence on ER-calcium as the source of nuclear calcium. Once again, we used thapsigargin to circumvent a regulated ER calcium release and observed no additional effect on Bnip3ΔExon3-induced nuclear calcium accumulation, indicating that this is an active process mediated by Bnip3ΔExon3 ( Figure 7I ). Finally, we examined the interconnectivity of misoprostol and Bnip3ΔExon3 in this signaling pathway. We found that treatment with misoprostol also increased nuclear calcium levels. Importantly, this effect was diminished by siRNA knockdown of Bnip3ΔExon3 ( Figure 7J , K). Collectively, these observations provide evidence that Bnip3ΔExon3 promotes ER-to-nuclear calcium transfer, while Bnip3-FL promotes ER-to-mitochondrial calcium transfer. Furthermore, mitochondrial translocation of BCL-2 might be an important intermediate step in the distinct regulation of calcium signals initiated by Bnip3ΔExon3.
Bnip3ΔExon3 promotes cardiomyocyte hypertrophy:
In order to understand the cellular consequences of Bnip3ΔExon3-induced nuclear calcium accumulation, we evaluated two transcriptional regulators known to be regulated in a calcium-dependent manner. Theoretically, these regulators (NFATc3 and HDAC5) offer a tool to test the potential of Bnip3ΔExon3-regulated calcium signalling as a modulator of gene expression; biologically, these tools serve as indications of the cellular significance of this regulatory pathway. First, the transcription factor NFATc3 is activated by the calcium-calmodulin activated phosphatase calcineurin, promoting nuclear translocation. Second, the class II histone deacetylase, HDAC5, is exported from the nucleus upon phosphorylation by calcium-calmodulin activated kinases (CaMKs). Thus, we evaluated the effect of Bnip3ΔExon3 on the subcellular localization of these proteins as an indication of their activity by way of fluorescent fusion proteins of NFATc3 (NFAT-YFP) and HDAC5 (HDAC5-GFP). We observed that expression of Bnip3ΔExon3 increased the nuclear localization of NFAT-YFP ( Figure 8A, B) , and increased the cytosolic localization of HDAC5-GFP ( Figure 8C, D) . These observations suggest that Bnip3ΔExon3-induced nuclear calcium has the potential to alter gene expression. Interestingly, both NFATs and class II HDACs have been implicated as regulators of cardiomyocyte growth during development and cardiac disease. Thus, as a test of the cellular significance of this regulatory axis we transduced primary neonatal cardiomyocytes with a lentivirus delivering Bnip3ΔExon3 and performed immunofluorescence with the sarcomeric myosin antibody MF-20 to measure cell area. Shown in Figure 8E and F, we observed a statistically significant increase in cardiomyocyte cell area with Bnip3ΔExon3 expression. Furthermore, we evaluated the expression of two classical marker genes of cardiac hypertrophy and reactivation of the 'fetal gene program', αand β-myosin heavy chain (MHC), by real-time PCR. In this regard, a shift from α-MHC (Myh6) to β-MHC (Myh7) serves as an indication of the reversion from 'adult' to 'fetal' gene expression programs 39, 40 . We observed that Bnip3ΔExon3 increased Myh7 expression and reduced Myh6 expression ( Figure 8G ). This resulted in an increase in the MHC ratio (Myh7/Myh6; 1.66) with Bnip3ΔExon3 transduction. Similarly, we observed that treatment of primary cardiomyocytes with misoprostol also increased cell area, and the magnitude of this effect was matched in cells treated with the well-established hypertrophy-inducer phenylephrine (PE) ( Figure  8H ). Collectively, these findings suggest that nuclear accumulation of calcium elicited by the small Bnip3 splice variants operates to regulate the activity of transcription regulators and has the potential to control cardiomyocyte growth, in addition to their roles in cell survival.
Discussion
The cellular response to hypoxia involves both adaptive cell survival phenomenon and regulated cell death; however, the mechanisms dictating these opposing cell phenotypes during development and disease remain poorly defined. Here we provide evidence that activation of prostaglandin signaling through misoprostol treatment induces pro-survival NF-κB gene expression during hypoxia, resulting in reduced expression of the pro-death Bnip3-FL splice variant and increased expression of pro-survival small Bnip3 variants ( Figure 9A ). Our data also implicates the combined action of HIF1α and NF-κB P65 to promote cell survival, whereas activation of HIF1α alone induces Bnip3-FL expression and cell death. We also demonstrate that the BNIP3 gene can be differentially spliced in human versus rodent cells.
Since its discovery, it has been noted that Bnip3 could induce context-dependent apoptotic or necrotic cell death 14, 37 . Early studies evaluating Bnip3 determined its subcellular location is predominantly mitochondrial, and cells expressing Bnip3 displayed features consistent with apoptosis 37 . However, more detailed analysis of Bnip3 revealed that it could activate cell death from extra-mitochondrial sites and cells expressing Bnip3 display a necrotic cell phenotype, particularly when Bnip3 is targeted to the ER with the cytochrome-b5 transmembrane domain 12, 14 . Importantly, cell death elicited by Bnip3 is attenuated with the mitochondrial permeability transition pore inhibitor cyclosporine-A and the mitochondrial calcium uniporter blocker Ru360 12, 14 ; whereas, cells expressing BNIP3 are resistant to caspases inhibitors, such as zVAD-fmk 14 . These findings are consistent with the notion that Bnip3 is an important regulator of mitochondrial permeability transition-regulated necrosis, through a calcium-dependent mechanism 28, 29 . Current models of Bnip3 function suggest that Bnip3 regulates apoptosis and mitophagy when localized at the mitochondria, and macro-autophagy and necrosis when localized at the ER membranes 13 . However, a definitive mechanism describing how Bnip3 is translocated to either the mitochondria or ER is lacking, and many questions remain regarding cell-type specific differences in Bnip3 function.
The results of the present study expand these previous observations and suggest that alternative splicing of Bnip3 is an important mechanism to control cellular calcium homeostasis, cell death, and cell growth. We observed that both Bnip3-FL and Bnip3ΔExon3 deplete ER calcium content. However, Bnip3-FL preferentially transfers calcium to the mitochondrial matrix and triggers mitochondrial permeability transition and necrosis; whereas, Bnip3ΔExon3 serves to block mitochondrial accumulation and promote nuclear calcium transfer leading myocyte cell growth ( Figure 9B ). However, the role of the endogenous Bnip3 splice variants has not been fully validated in vivo, and the function of specific splice variants has yet to be characterized by genetargeting studies. Nonetheless, these findings serve to unify the seemingly disparate observations of others who have observed that IP3R-dependent calcium release can induce cell death 33, 34 , and cardiac hypertrophy 41 . Our findings suggest that the splicing of Bnip3, and the cellular location of BCL-2, can influence cell fate by dictating where the IP3R-dependent calcium release accumulates, either in the mitochondria or the nucleus. However, additional in vivo experimentation is required to evaluate the role of Bnip3 splicing in hypertrophic regulation and determine under which biological contexts this Bnip3-dependent mechanism operates, as other BCL-2 family members, such as Bnip3L/Nix, likely contribute to cardiac calcium homeostasis 36 .
Another important observation in the present study is the identification of the human BNIP3ΔExon2 splice variant. Although we identified several similarities between BNIP3ΔExon2 and Bnip3ΔExon3, such as inhibition of cell death, prevention of ER-mitochondrial calcium transfer, and nuclear calcium accumulation, potential differences likely exist. In silico domain mapping revealed conserved N-terminal and C-terminal sequences; however, significant sequence differences exist, including a predicted nuclear localization sequence present in BNIP3ΔExon2 that is not present in Bnip3ΔExon3, and the LIR domain which is present in Bnip3ΔExon3 but not BNIP3ΔExon2. Further experimental work is required to fully define how BNIP3ΔExon2 and Bnip3ΔExon3 functions are distinct. Interestingly, recent work regarding the Bnip3 homologue, Bnip3L/Nix, has demonstrated that its small splice variant, named sNix, alters gene expression to promote cell survival in an NF-κB-dependent manner 42 . Collectively, this suggests an interplay between Bnip3 and Bnip3L/Nix splicing and NF-κB-dependent survival gene expression. Moreover, the expression ratio of Nix to sNix was determined to be approximately 10:1, which is consistent with our findings regarding ratio of Bnip3 to its small survival splice variants, and suggests that these small splice variants exert their physiological effects through gene expression amplification rather than direct inhibition of the full-length isoforms 42 .
Recent progress has been made regarding the mitochondrial permeability transition pore structure and function, and several studies have defined the importance of permeability transitiondependent necrosis in the pathophysiology of ischemic cardiac and cerebrovascular diseases 29 . Our data suggests that Bnip3 splicing plays an important role in the complications arising from neonatal hypoxia. However, additional studies are needed to determine if this mechanism operates to control permeability transition, necrosis, and/or cell growth in other pathologies. Given the diverse roles of Bnip3 splice variants regulating mitochondrial function, autophagy, and cell growth, dysregulation of this genetic pathway may have broad implications involving ischemic cardiovascular and cerebrovascular diseases, as well as cancer biology.
Materials and Methods
In vivo neonatal hypoxia model: All procedures in this study were approved by the Animal Care Committee of the University of Manitoba, which adheres to the principles for biomedical research involving animals developed by the Canadian Council on Animal Care. Litters of Long-Evans rat pups (N=5) and their dam were placed into a hypoxia chamber with 10% oxygen delivery, at post-natal day-3 (PND3) for 7 days. Control pups (N=5) were left in normoxic conditions at 21% oxygen 23, 24 . Animals received subcutaneous injections of 10 µg/kg misoprostol, or saline control, for 7 days. At PND10 animals were euthanized and perfused with saline for tissue collection.
Plasmids and virus production:
The PKA biosensor (pPHT-PKA) was a gift from Anne Marie Quinn (Addgene #60936) 25 . The plasmids for human P65 expression including: GFP-RelA, T7-RelA, T7-RelA(S276A), and PCMV4-3 HA/IkB-alpha(SS32,36AA) were gifts from Warner Greene (Addgene #23255, 21984, 24153, 24143) 43, 44 . The plasmid for HIF1α (HA-HIF1α-pcDNA3) was a gift from William Kaelin (Addgene #18949) 45 . The mitochondrial (CMV-mito-CAR-GECO1), endoplasmic reticulum (CMV-ER-LAR-GECO1), and nuclear (CMV-NLS-R-GECO) targeted calcium biosensors were gifts from Robert Campbell (Addgene #46022, 61244, and 32462) 35, 46, 47 . Flag-BCL-2 was gift from Clark Distelhorst (Addgene #18003) 48 . pMSCV-puro-mMCL1-WT was a gift from Joseph Opferman (Addgene #45817) 49 . NFATc3 fused to YFP (NFAT-YFP) was a gift from Tetsuaki Miyake, and HDAC5-GFP was provided by E. Olson. The mouse myc-Bnip3-FL and HA-Bnip3ΔExon3 (Accession #MF156210) were described previously (Addgene #100796, #100793) 22 . The pLenti-Bnip3ΔExon3 virus was generated by ligating a PCR amplicon (HA-Bnip3ΔExon3) into the pLentipuro back bone, which was a gift from Ie-Ming Shih (Addgene #39481) 50 . Virus was packaged and purified in the University of Manitoba Lentiviral Vector Viral Particles & Production Core. Human HA-BNIP3-FL and HA-BNIP3ΔExon2 (Accession #MF593120) (Addgene #100781, #100782) were generated by PCR using cDNA from HUECs and primers containing EcoRI and XhoI restriction enzymes sites in the forward and reverse primers, respectively. Primers include BNIP3 Forward: 5'-TATGCGGAATTCATGTCGCAGAACGGAGCGCCCGGGAT-3', BNIP3 Reverse: 5'-AATCCGCTCGAGTCAAAAGGTGCTGGTGGAGGTTGTC-3'; BNIP3ΔExon2 Reverse: 5'-AATCCGCTCGAGTCAAGATGCTTTCAACTTCTTTCC-3'. PCR products were cut and ligated into pcDNA3, in frame with an N-terminal HA tag, described previously 51, 52 .
Cell culture, transductions and transfections:
HCT-116 cells were maintained in McCoy's 5A medium (Hyclone), containing penicillin, streptomycin, and 10% fetal bovine serum (Hyclone), at 37 °C and 5% CO 2 . H9c2 and 3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Hyclone), containing penicillin, streptomycin, and 10% fetal bovine serum (Hyclone), at 37 °C and 5% CO 2 . Rat primary ventricular neonatal cardiomyocytes (PVNC) were isolated from 1-2 day old pups using the Pierce Primary Cardiomyocyte Isolation Kit (#88281). All cells were transfected using JetPrime Polyplus reagent, as per the manufacturer's protocol 30 . Overexpression of Bnip3ΔExon3 in PVNC cells was carried out using pLenti-puro-Bnip3ΔExon3 lentiviral particles, alongside control lentiviral particles (Santa Cruz, sc-108080) to control for the effects of transduction alone. RNAi experiments targeting Bnip3-FL and Bnip3ΔExon3 were performed using siRNA targeting the 3 rd exon (sense sequence:
UCGCAGACACCACAAGAUA) and the exon 2-4 junction (5'-CACUGUGACAGUCUGAGGA) respectively (Dharmacon). A scrambled siRNA was used as control (Santa Cruz sc-37007). siRNA's were transfected into cells using JetPrime Polyplus reagent, as per the manufacturer's protocol 30 . For misoprostol treatments, 10mM misoprostol (Sigma) in phosphate buffered saline (PBS; Hyclone) was diluted to 10µM directly in media and applied to cells for 20 hours 22 . For H89 treatment, a 10mM stock of H89-dyhydrochloride hydrate (Sigma) in PBS, was diluted to 10µM directly in media. For cobalt chloride (CoCl 2 ) treatment, a 200mM stock solution of cobalt(II) chloride hexahydrate (Sigma) in PBS, was diluted to 200µM directly in media and applied to cells. CoCl 2 concentration was selected based on previously published data looking at HIF1α induction 53 . For calcium imaging experiments, 1µM Thapsigargin (Sigma) was applied directly to cells for 4 hours, while 2 µM 2-APB (Sigma), 10µM Ru360 (Sigma), and 10µM disodium 4,4′-diisothiocyanatostilbene-2,2′-disulfonate (DIDS, Sigma) were applied directly to cells for 16 hours. For cardiac hypertrophy experiments, a 10mM stock of phenylephrine (Sigma) in PBS, was diluted to 10µM directly in media.
Fluorescent staining and live cell imaging:
Hoechst 33342, TMRM, calcein-AM and Ethidium Homodimer-1 were all purchased from Biotium and applied using manufacturer's protocol 30, 54 . MitoSOX was purchased from Life Technologies and was applied to cells for a 10-minute incubation to assess mitochondrial superoxide 30 . Calcein-Cobalt Chloride (CoCl 2 ) staining was used to assess mitochondrial permeability transition, which is achieved through quenching cytosolic calcien-AM signal with 5µM CoCl 2 described previously 30 . Immunofluorescence with Anti-MF-20 (DSHB # AB_2147781) was used with fluorescent secondary antibody conjugated to Alexa Fluor 555 (Themo # A-31570) to assess cardiac hypertrophy in fixed and permeabilized PVNM cells. All imaging experiments were done on an Olympus IX70 inverted microscope with QImaging Retiga SRV Fast 1394 camera using NIS Elements AR 3.0 software. Quantification, scale bars, and processing including background subtraction, was performed on Fiji (ImageJ) software.
Immunoblotting:
Protein extractions were achieved using a RIPA lysis buffer combined with Phenylmethanesulfonyl fluoride (PMSF, Sigma), Sodium orthovanadate (NaVO, Sigma) and phosphatase inhibitor cocktail (PIC, Santa Cruz). Homogenization was required in the case of tissue protein extraction. Mitochondrial/cytosolic fractionation was done using a Mitochondrial Isolation Kit (Qiagen Qproteome # 37612), while nuclear/cytosolic fractionation was done using a NE-PER Nuclear and Cytosolic Extraction Kit (Pierce # 78833), as described previously 21, 55, 56 . Protein content was determined using a Bio-Rad Protein Assay Kit. Extracts were resolved via SDS-PAGE and later transferred to a PVDF membrane using an overnight transfer system. Immunoblotting was carried out using primary antibodies in 5% powdered milk or BSA (as per manufacturer's instructions) dissolved in TBST. Horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories; 1:5000) were used in combination with enhanced chemiluminescence (ECL) to visualize bands 55, 56 . The following antibodies were used: Bnip3-FL and BNIP3ΔExon2 (CST # 44060), P65 (CST # 8242), P65 Phospho-Ser276 (Assay BioTech # A7169), HIF1α (CST # 14179), Flag (CST # 2368), HA (CST # 3724), AIF (CST # 5318), MEK (CST # 8727), Histone-H3 (CST # 4499), Tubulin (CST # 86298), and Actin (Santa Cruz sc-1616). For the detection of rodent Bnip3 splice variants a custom rabbit polyclonal antibody was generated by Abgent using the following peptide sequence CSQSGEENLQGSWVE.
Mitochondrial respiration:
Mitochondrial respiration in PVNM cells was assessed using the Seahorse XF-24 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA), as described previously 30 . Calculated respiration rates were determined as per manufacturer's instructions (Mito Stress Kit; Seahorse Bioscience).
Reverse Transcription PCR:
Total RNA was extracted from cells and pulverized tissues by the TRIzol extraction method and genomic DNA was removed via the RNeasy Mini Kit (Qiagen), including an On-Colum DNase I Digestion (Qiagen). For reverse transcription PCR (RT-PCR), purified mRNA was reverse transcribed using Maxima Enzyme (Thermo), followed by PCR using Taq polymerase (New England Biolabs). Amplified RNA was then run on a 2% agarose gel with GelRed nucleic acid gel stain (Biotium). The cloning primers, described above, were used to detect human BNIP3 splice variants. Mouse Bnip3 primers were: Forward: 5'-GCCGGAATTCATGTCGCAGAGCGGGGAG-3', Bnip3-FL Reverse: 5'-CGGCGCTCGAGTCAGAAGGTGCTAGTGGAAGTTGTC-3', and Bnip3ΔExon3 Reverse: 5'-CGGCGCTCGAGTCAGGATACTTTCAACTTCTCTTCTTCTCTC-3' Primers used for rat heart tissue were: 5'-TTCCAGCTTCCGTCTCTATTT-3' and 5'-TCAGGATACTTTCAACTTCTCTTCT-3'. For quantitative real-time PCR (qPCR) targeting myosin heavy chain expression, mRNA was extracted from cells using TRIzol then reverse transcribed into cDNA. Following DNase treatment, cDNA was combined with SYBR Green Supermix (Thermo) and mRNA was amplified using the ABI 7500 Real-Time PCR system (Applied Biosystems). Primers were: Rat myosin heavy chain 6 forward: 5'-GAGGAATAACCTGTCCAGCAG -3', and reverse: 5'-TACAGGCAAAGTCAAGCATTC -3'. Rat myosin heavy chain 7 forward: 5'-CCAACACCAACCTGTCCAAG-3', and reverse: 5'-CAAAGGCTCCAGGTCTCAGG -3'. Rat B-Actin forward: 5'-CTGTGTGGATTGGTGGCTCTA -3', and reverse 5'-AAAACGCAGCTCAGTAACAGTCC -3'.
Statistics:
Data are presented as mean ± standard error of the mean (S.E.M.). Differences between groups in imaging experiments with only 2 conditions were analyzed using an unpaired t-tests, where (*) indicates P<0.05 compared with control. In the case of the cell size experiment, a 2-tailed t-test with Welches correction was used to compare the differences between conditions. Experiments with 4 or more conditions were analyzed using a 1-way ANOVA, with Tukey's test for multiple comparison, where (*) indicates P<0.05 compared with control, and (**) indicates P<0.05 compared with treatment. All statistical analysis was done using GraphPad Prism 6 software. 
Figure Legends
